GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (FRA:NVV1) » Definitions » Valuation Rank

Novavax (FRA:NVV1) Valuation Rank


View and export this data going back to . Start your Free Trial

What is Novavax Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Novavax Valuation Rank Related Terms

Thank you for viewing the detailed overview of Novavax's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (FRA:NVV1) » Definitions » Valuation Rank
Comparable Companies
NRIX SYRE VRDN DAWN VIR NTLA FTRE ADPT ARVN ARDX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
NVAX:USA NVAX:Mexico NVV1:Germany NVV1:Bulgaria NVAX:Austria
Address
700 Quince Orchard Road, Gaithersburg, MD, USA, 20878
Website
https://www.novavax.com
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.